We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Implantable Ultrasound Technology Opens Blood-Brain Barrier

By HospiMedica International staff writers
Posted on 23 Dec 2019
A new study shows how an ultrasound-mediated procedure can increase Paclitaxel delivery to the brain five-fold by cracking open the blood brain barrier (BBB).

Researchers at Northwestern University (NU; Chicago, IL, USA), the Institut du Cerveau et de la Moelle Epinière (ICM; Paris, France), and other institutions conducted a study to examine if low-intensity pulsed ultrasound (LIPU) with microbubble injection could transiently disrupt the BBB to allow improved drug delivery to the brain for the treatment of glioma. More...
The biodistribution, toxicity, and efficacy of LIPU delivery was studied for two formulations of paclitaxel, albumin-bound paclitaxel (ABX), and paclitaxel dissolved in cremophor (CrEL-PTX).

The sonications were performed using the CarThera (Paris, France) One MHz LIPU device (Developed at ICM). The tiny ultrasound device is implanted during surgery into a window in the skull that does not contain bone, and is used in combination with microscopic gas bubbles injected into the blood at the same time the ultrasound begins. When the bubbles hit the sound waves, these vibrate and mechanically disrupt the BBB, allowing penetration of drug molecules. The BBB disruption lasts for several hours after the sonication, and is reversible. The ultrasound emitter remains in the skull for repeated drug deliveries.

For the study, antiglioma activity was evaluated in nude mice bearing intracranial patient-derived glioma xenografts (PDX), with fluorescein used to confirm and map BBB disruption. Toxicity of LIPU-delivered paclitaxel was assessed through clinical and histologic examination of the treated mice. The results revealed that ultrasound-mediated BBB disruption enhanced paclitaxel brain concentration 3-to-5 fold for both formulations, and further augmented the therapeutic benefit of ABX. Repeated courses of LIPU-delivered CrEL-PTX and CrEL alone were lethal in 42% and 37.5% of mice, respectively, whereas similar delivery of ABX at an equivalent dose was well tolerated. The study was published on December 12, 2019, in Clinical Cancer Research.

“Glioblastoma currently has no cure, and when the tumor recurs there are not many treatment options. We urgently need effective new treatments,” said senior author Adam Sonabend, MD, of the NU Feinberg School of Medicine and a. “ABX is the preferred formulation for further investigation in the clinical setting, due to its superior brain penetration and tolerability compared with CrEL-PTX.”

The BBB is comprised of specialized endothelial cells that form the capillary microvasculature of the central nervous system (CNS), and is essential for brain function. It selectively prevents substances from entering the blood and brain, only allowing such essential molecules as amino acids, oxygen, glucose and water through. On the other hand, it also poses the greatest impediment in the treatment of many CNS diseases, because it commonly blocks entry of therapeutic compounds.

Related Links:
Northwestern University
Institut du Cerveau et de la Moelle Epinière
CarThera



Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Digital Color Doppler Ultrasound System
MS22Plus
Bipolar Coagulation Generator
Aesculap
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.